Temasek-backed Chinese biotech firm D3 Bio raises $62m in Series A+ round

Temasek-backed Chinese biotech firm D3 Bio raises $62m in Series A+ round

Photo by Hal Gatewood on Unsplash

Eudora Wang

09 April, 2024

Edited by: Paramita Chatterjee

biotechBoyu Capitalcancer treatmentD3 BioMedicxiOncologyTemasek Holdings

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

You may also like

Read more from Greater China

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.